Detail akcie ProQR Therapeutics online

Business Summary: ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, ProQR Therapeutics NV revenues increased from EUR9.5M to EUR19.5M. Net loss decreased 1% to EUR27.8M. Revenues reflect Revenue increase from EUR6.5M to EUR18.9M. Lower net loss reflects RNA based Therapeutics segment loss decrease of 4% to EUR30.5M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR0.35 to -EUR0.32.